EGFR and non-small cell lung carcinoma: This test is used to guide the use of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors on the basis of specific EGFR-sensitizing mutations in patients with non-small cell lung cancer (NSCLC).